InvestLog
Back to Market返回行情

ACOG Alpha Cognition Inc. Common Stock

USFinancial Services
$8.52+0.24%ClosedMarket Cap: $132.3M

As of 2026-07-09 16:00

Why ACOG matters now

Alpha Cognition Inc. Common Stock (ACOG) is a US stock in Financial Services. The latest InvestLog snapshot shows $8.52 with +0.24% on the session and $132.3M in market capitalization; recent performance reads 1-month +19.14% and YTD +6.31%.

The latest financial table shown here is Q1 2026, with revenue of $3.5M, net income of $-6.5M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.3%.

The latest indexable market news headline is "Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board" from GuruFocus.

Additional event context on this page matters because analyst consensus is Buy with a median target of $13.00; recent insider activity includes Opaleye Management Inc. filing P-Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

2.62

P/S

9.91

EV/EBITDA

-1.96

DCF Value

$9.26

FCF Yield

-28.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

86.4%

Operating Margin

-250.1%

Net Margin

-232.2%

ROE

-54.1%

ROA

-36.3%

ROIC

-42.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$3.5M$-6.5M$-0.32
Q4 2025$2.8M$-6.9M$-0.31
FY 2025$10.2M$-20.7M$-1.17
Q3 2025$2.8M$-1.3M$-0.08

Analyst Ratings

Consensus

Buy

Target (Consensus)

$13.00

Target (Median)

$13.00

Target Range

$12.00 - $14.00

Strong Buy: 1Buy: 2Hold: 0Sell: 0Strong Sell: 0
HC Wainwright & Co.Buy
2026-05-22
HC Wainwright & Co.Buy
2025-12-19
HC Wainwright & Co.Buy
2025-10-20

Trading Activity

Insider Trades

Opaleye Management Inc.10 percent owner
Buy2026-06-15
Opaleye Management Inc.10 percent owner
Buy2026-06-15
Opaleye Management Inc.10 percent owner
Buy2026-06-15
Opaleye Management Inc.10 percent owner
Buy2026-06-11
Opaleye Management Inc.10 percent owner
Buy2026-06-11

Related Stocks

CAPN
Cayson Acquisition Corp Ordinary shares
$86.5M
CHPG
ChampionsGate Acquisition Corporation Class A Ordinary Share
$103.8M
DTSQ
DT Cloud Star Acquisition Corporation
$100.3M
FGBI
First Guaranty Bancshares, Inc.
$173.0M
MAAS
Maase Inc.
$5.26B

Latest News

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the BoardGuruFocus · 2026-06-23
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the BoardBusiness Wire · 2026-06-23
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's DiseaseBusiness Wire · 2026-06-16
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's DiseaseGuruFocus · 2026-06-09
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's DiseaseBusiness Wire · 2026-06-09

Company Info

Sector

Financial Services

Industry

Financial - Conglomerates

Country

CA

Exchange

—

Beta

2.37

Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm focused on creating therapies for neurological conditions such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Among its offerings is ZUNVEYL (benzgalantamine), intended for the management of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. The company is also progressing with other therapeutic programs, including ALPHA-0602, a gene therapy specifically for ALS, and ALPHA-0702 and ALPHA-0802, which are granulin epithelin motifs targeting various neurodegenerative disorders. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before rebranding to Alpha Cognition Inc. in March 2021. Its corporate base is located in Vancouver, Canada.